// App-Quantinova.ai

: Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Researchers

Presenter

  • Alexandre Vinaud Hirayama

Principal Investigators

  • Jordan Gauthier

  • Jenna M. Voutsinas

  • Qian Vicky Wu

  • Erik L. Kimble

  • Barbara S. Pender

  • Delaney R. Kirchmeier

  • Henna A. Di

  • Ryan D. Cassaday

  • Aude G. Chapuis

  • Damian J. Green

  • Hans-Peter Kiem

  • Filippo Milano

  • Mazyar Shadman

  • Brian G. Till

  • Stanley R. Riddell

  • David G. Maloney

  • Cameron J. Turtle

Medical Centers

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • UW/FHCRC, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 19

  • Programmed death-ligand 1

  • Twist-related protein 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Durvalumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved